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Abstract 
BACKGROUND: International discourse concerning the evolution in hepatitis C 
virus (HCV) therapy has tended to focus on improving outcomes, shortened 
treatment length and reduced side-effects of interferon-free regimens.  How 
these treatments are being understood and experienced by the people receiving 
them has so far been overlooked.  This study therefore aimed to explore the 
lived experience of individuals taking interferon-free HCV therapies. 
METHODS: Data were generated through 16 semi-structured interviews with a 
purposive sample of eight participants, recruited from a university hospital in 
Scotland.  The interviews took place between June 2015 and March 2016, 
before and after a period of interferon-free HCV treatment.  The data was 
interrogated using a thematic analysis, underpinned by social 
phenomenological theory. 
RESULTS: Three overriding themes were identified.  ‘Expectations and 
realisations’ characterised the influence that interferon continued to cast over 
interferon-free treatment, contrasting the practicalities of taking interferon-free 
therapy with preconceived notions.  ‘An honour and a pleasure’ portrayed a 
positive experience of an undemanding therapy, yet amongst those with a 
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history of drug use, was also positioned as a privilege, associated with feelings 
of luck and guilt. ‘Treatment needs’ illustrated the strategies participants used to 
search for treatment efficacy, and the value those with a significant history of 
drug use placed on support.  One nonconforming case is then discussed to 
enhance rigour and trustworthiness. 
CONCLUSION: This is the first qualitative exploration of the experience of 
interferon-free HCV treatment reported globally.  The results from this study 
suggest a cultural lag exists between the pharmacological developments which 
have been witnessed, and societal understandings of them.  This has 
implications for the way services meet the needs of, and offer therapy to, HCV 
positive individuals. 
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Background 
Recent years have witnessed a rapid evolution in the treatment options 
available for people living with the hepatitis C virus (HCV) (Chung & Baumert, 
2014; Pawlotsky et al, 2015).  The summer of 2011 signalled the beginning of a 
new era in the fight against the disease, with the first direct-acting antivirals 
(DAAs) entering clinical practice in many high-income nations (Chung & 
Baumert, 2014).  Although these drugs were initially added into the existing 
treatment regimen of pegylated interferon-α and ribavirin, swift pharmacological 
developments resulted in the advent of second generation DAAs which no 
longer required the notoriously unpleasant interferon-α backbone (Pawlotsky et 
al, 2015).  These advances shortened the length of treatment to twelve weeks 
or less; reported a considerable reduction in side-effects; and improved 
sustained virological response (SVR) rates to over 90% (Asselah et al, 2016). 
 
Globally, multiple barriers to accessing these medications at the patient-, 
provider- and governmental-level have led to only a minority of infected patients 
receiving them.  Patient-level barriers include such issues as a lack of 
symptoms and social stigmatisation.  Provider-level barriers encompass factors 
such as physicians’ undue emphasis on purported contraindications to therapy 
(McGowan et al, 2013), such as exclusion criteria which penalise current 
injecting drug users.  However, the barriers found at the governmental-level, 
largely concerning the high costs of these medications, are often cited as the 
most significant global barrier to patients receiving the best and most effective 
treatments available (Fung, 2015; Reau & Jensen, 2014).  In Scotland, the high 
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medication costs have led to restricted approval of a number of interferon-free 
regimens, allowing access for individuals with HCV genotype 1, but denying 
access to individuals with other HCV genotypes unless deemed ineligible for 
interferon-based therapy (Healthcare Improvement Scotland and NHS National 
Services Scotland, 2015).  However, access to treatment is only one facet of 
achieving successful outcomes.  Gaining insights into how HCV treatment is 
experienced and understood is also crucial when considering how treatments 
can be successfully delivered and monitored in clinical practice. 
 
Qualitative investigation into the experience of taking interferon-based 
treatments has provided valuable insight into this arduous and demanding 
course of therapy for many years.  The findings from this body of work have 
demonstrated the severity and persistence of a range of both physical and 
psychological side-effects, including chronic fatigue, flu-like symptoms, myalgia, 
insomnia, alopecia, weight loss, mood swings, anxiety, and depression 
(Fraenkel et al, 2006; Hopwood & Treloar, 2005; Kinder, 2009; Sheppard & 
Hubbert, 2006; Taylor-Young & Hildebrandt, 2009; Zickmund et al, 2006).  
Further, these studies have explored how this litany of treatment-related 
ailments has broader social implications.  They describe how interferon-based 
therapy can affect an individual’s self-identity and their perception by others 
(Janke et al, 2008; Sheppard & Hubbert, 2006), can strain relationships with 
family and friends (Sgorbini, O’Brien & Jackson, 2009), and contribute to social 
isolation (Fraenkel et al, 2006; Janke et al, 2008; Taylor-Young & Hildebrandt, 
2009).  Accounts of interferon-based regimens are frequently framed as “horror 
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stories” within the literature, emphasising the gruelling nature of treatment and 
the fear and anxiety it can produce (Kinder, 2009). 
 
To date, there has been no similar exploration into the experience of taking 
interferon-free therapies.  The prevailing discourse surrounding these new 
treatments emphasises their ease and tolerability (Coppola et al, 2015; Lam et 
al, 2015).  However, this understanding is largely based on the results of 
quantitative health-related quality of life measures (Whiteley et al, 2015; 
Younossi et al, 2015a), which provide little context as to how an ‘easier’ 
treatment is actually experienced, and what it means for the individuals taking 
the medications.  The aim of this study therefore, is to explore the lived 
experience of individuals taking interferon-free HCV therapies. 
  
Methods 
Theoretical Framework 
The study is underpinned by a social phenomenological framework.  This 
sociological approach to phenomenology was first espoused by Alfred Schütz 
(1967), and emphasises the profound influence of the social world in 
establishing the meaning of a phenomenon.  This approach to research rotates 
phenomenology outwards, exploring how the understanding of a phenomenon 
is founded in the inter-subjective social world, and challenges the eidetic 
phenomenological assumption that intentional consciousness is the driving 
force in constituting an object’s meaning (Ajiboye, 2012).  Social 
phenomenology seeks to explore the commonalities that are found in the 
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subjective life-worlds of more than one actor, providing a more objective 
description and understanding of a subjective experience (Shaw & Connelly, 
2012). 
 
Participants 
This theoretical framework necessitated a qualitative study design, comprising 
in-depth, face-to-face, semi-structured interviews with eight participants, both 
before and after their period of treatment.  Participants were purposefully 
sampled from an infectious diseases outpatient clinic based at a university 
hospital in Scotland.  Inclusion criteria consisted of being aged 16 years or over, 
diagnosed with HCV for more than six months, and able to converse in English.  
A maximum variation sampling strategy was employed which aimed to select a 
heterogeneous sample of participants, who differed in their experience of 
previous HCV treatment, their mode of HCV acquisition and their date of 
diagnosis.  This sampling strategy assumes that common patterns that emerge 
from great variation are of particular interest and value in capturing the shared 
dimensions of a phenomenon (Patton, 2015).  Diversity within the sample also 
allows for the comparative potential of the data to be capitalised upon (Mason, 
2002). 
 
Individuals who fulfilled the inclusion criteria were approached by their regular 
HCV nurse or doctor during routine clinic appointments, and consent obtained 
for their details to be passed to the researcher (DW) if interest was shown in 
participating.  Records were not kept of how many individuals were approached 
 
 
8 
 
but declined to participate at this stage.  Interested parties were then 
telephoned by the researcher, and a meeting arranged where the purpose of 
the study was explained, any questions answered, and written consent obtained 
to participate in one semi-structured pre-treatment interview, and to allow the 
researcher to contact them again with a view to conducting a further interview 
once their treatment was complete. 
 
Whilst all participants received interferon-free treatment, they did not all receive 
the same drug regimen.  During the study, national guidelines and local 
recommendations for HCV treatment with DAAs were repeatedly revised, 
resulting in changes to first-line therapy.  In addition, variations in regimen 
occurred in line with factors such as degree of liver disease and HCV genotype. 
Also, one participant undertook an unlicensed interferon-free regimen as part of 
a separate randomised controlled trial.  These factors resulted in the use of four 
different treatment regimens amongst the eight participants (table 1).  In order 
to protect participant anonymity, the details of which regimen each individual 
received have not been specified.  However, whether these regimens were 
single- or multi-tablet has been noted alongside participant quotes within the 
results. 
 
Interviews 
All interviews were conducted between June 2015 and March 2016 within a 
suitable room at the hospital outpatient clinic, and lasted a mean duration of 40 
minutes.  Topic guides were used, however the semi-structured approach 
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allowed participants the freedom to talk about their personal experiences as 
they wished.  The pre-treatment interviews covered HCV treatment knowledge 
and perceptions, previous experiences of HCV therapy, and thoughts and 
feelings about their proposed course of medication.  The questions posed to the 
participants were designed to be brief, simple and open-ended (e.g. “can you 
tell me what you know about hep C treatment?”) with their answers probed for 
further detail where appropriate.  Follow-up interviews focused on the 
participants’ experiences of treatment and their views on the treatment service.  
In addition, during the post-treatment interviews, transcript excerpts from the 
participant’s pre-treatment interview were used to revisit their specific 
expectations and thoughts about treatment from a different standpoint.  All 
interviews were conducted by DW, a registered nurse with ten years’ 
experience and who had worked as an HCV nurse specialist between 2009-
2013.  No access to paper or electronic patient case notes was permitted during 
the study.  The interviews were recorded using an encrypted digital audio-
recorder, and field notes were made upon completion and added to a research 
diary.  Audio-files of the interviews were transcribed verbatim by DW, during 
which any patient identifiable information was obscured from the narrative.   
 
Analysis 
Six phases of thematic analysis guided the analytical process (Braun & Clarke, 
2006).  Each transcript was initially read and reread in full by two researchers 
(DW and AW) in order to ensure subsequent coding and identification of themes 
remained firmly rooted in the narratives.  Coding was then conducted by DW 
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using NVivo v.10 software, and contained both deductive and inductive 
elements.  A broad coding framework was initially devised, informed by 
categories found in previous qualitative research focused on interferon-based 
therapy, such as ‘side-effects’ and ‘support’ (Whiteley et al, 2015).  It was 
considered reasonable to assume that wide-ranging categories such as these 
may be a feature of any treatment experience, transcending the specifics of the 
medications involved.  More detailed inductive codes were then added to this 
basic structure, formed from initial impressions of the corpus of data following 
further readings of the transcripts.  This approach served to assist with the early 
analysis of the data, however codes were also developed as novel and 
unexpected insights were met.  The pre- and post-treatment interviews were 
compared and contrasted, with both sets of data contributing to the generation 
of codes.  As analysis progressed, the deductive categories were dismissed, 
and the inductive codes combined, reviewed and revised.  This process drew 
groups of codes together to form a number of sub-themes.  Whilst depicted as a 
linear progression, the interviewing, transcribing and coding process occurred in 
parallel, with each activity informing the others.  This iterative process aided the 
identification of data saturation; no new codes were created during the coding of 
the final two transcripts as the narratives aligned with sub-themes already 
developed.  The sub-themes were then combined into candidate themes which 
were examined in relation to the corpus of data, field notes, and the research 
diary.  During this process, all four authors met regularly to review, challenge 
and interrogate the evolving analysis. 
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The trustworthiness and rigor of this endeavour were enhanced in a number of 
ways.  Regular meetings between all authors helped to contest and question 
any preconceptions or assumptions DW may have brought to the study due to 
his work history, consistent with the concept of bracketing.  Within social 
phenomenological research, the focus of study is the inter-subjective 
consciousness of which we, as researchers, are a part.  In order to study this 
inter-subjective consciousness, the concept of bracketing demands that we 
suspend belief in the existence of the world as we know it, and allow doubt that 
the world could be anything other than it appears (Ritzer & Ryan, 2011; Schütz, 
1967).  Meeting the participants on more than one occasion allowed initial 
interpretations to be revisited and verified, and ideas expressed pre-treatment 
to be reconsidered by both the participant and the interviewer.  Immersion in the 
full dataset by two of the authors ensured the findings remained data-driven and 
rooted in the narratives, rather than becoming too removed from the 
participants’ voice.  Where available, nonconforming cases were included in the 
analysis, to take into account an alternative and legitimate perspective on 
treatment. 
 
Ethical approval 
The study was reviewed and approved by the South East Scotland NHS 
Research Ethics Committee 01 (15/SS/0010) and by Edinburgh Napier 
University Research Ethics Committee.   All participants were offered a £15 
supermarket gift voucher for each interview they completed in line with national 
guidelines. 
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Results 
The characteristics of the sample are shown in table 2.  Each individual 
participated in two interviews, pre- and post-treatment, with no participant drop 
out during the study.  The themes which resulted from the analysis: 
expectations and realisations; an honour and a pleasure; and treatment needs, 
will now be examined. 
 
Theme: expectations and realisations 
The participants’ initial impressions of HCV treatment were unvaryingly 
negative, and bound to the interferon era.  They recounted a demanding and 
arduous course of therapy, gathered from various ‘horror stories’, or through 
witnessing others taking interferon-based treatment first-hand: 
 
I talked to people an’ all, all I got to hear was – this interferon is killing 
me, this interferon is killing me, I don’t know if I can keep on doing this. 
 
(Gary, multi-tablet regimen) 
 
Despite each participant receiving an interferon-free regimen, and being 
prepared and counselled for such by their healthcare team, the discourse 
surrounding treatment expectations was entangled with societal understandings 
of interferon-based therapy.  The influence of the drug that defined and 
characterised HCV treatment for over 20 years was prominent within the 
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narratives.  ‘Normal’ life would be forfeit for the duration of their interferon-free 
therapy, and the potential cure would come at a short-term cost: 
 
…I mean, if I spent three months of feeling a bit groggy, tired and 
miserable and I come out in the end, with err, you know, with err, good 
err, blood, err then it’s, you know, it’s worth that sacrifice… 
 
(John, multi-tablet regimen) 
 
Common side-effects of interferon were referenced explicitly as expectations for 
interferon-free treatments, with discussion of practical preparations to forestall 
the impact of these perceived inevitabilities commonplace.  For Stewart, the 
strength of his beliefs around the detrimental effect of treatment on his 
wellbeing was demonstrated in the meticulous planning that accompanied his 
first dose of the drugs: 
 
First tablet, went home, sick bowel, towel, duvet, tissues, waiting for it to 
come on (…) I prepared ready to be sick, I’d, I’d sent my partner away in 
case I was, really ill, know, kind a’, I don’t want a’ be sick or, or 
screaming at people.  I thought I was gonna be agitated, angry... 
 
(Stewart, single-tablet regimen) 
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Interferon was styled as a powerful and toxic drug within the narratives, and this 
perception of pharmacological strength was maintained when discussion turned 
towards DAAs.  The perceived strength of these drugs equated with the 
expectation of physiological collateral damage.  The idea of ‘no pain no gain’ 
prevailed.  An unpleasant, demanding and strenuous period of treatment must 
surely result from drugs formidable enough to eradicate HCV.   
 
For the majority of participants, the realisation of their worst fears and 
expectations did not materialise during their period of therapy, however a 
discourse surrounding treatment side-effects did become evident.  Examination 
of these narratives revealed a generally mild and manageable experience, 
significantly removed from the imagined horrors of therapy which had been so 
vividly constructed.  Side-effects were rarely stressed or emphasised, more 
commonly mentioned in passing or casually alluded to as minor 
inconveniences.  Descriptions of specific physical ailments were embedded 
within concurrent narratives of feeling well, and having little to complain about: 
 
…because physically I was fine, I cannae say there was anything really 
bad, the first two weeks, the headaches an’ I got quite a lot a’ bleeding 
noses, but then I jus’ started sort a’ taking painkillers for the headaches, 
then…when I came [to the clinic], I had quite a bit a’ constipation, so 
they gave me something for that, but that was it, nothing else. 
 
(Danielle, single-tablet regimen) 
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In addition to physical side-effects, a number of participants also related 
accounts of low mood and transient depression during treatment, however 
potential explanations for these ailments encompassed more than the 
pharmacology of the drugs.  The physical act of taking HCV therapy brought the 
disease to the forefront of participants’ minds, and meant confronting a reality 
many had previously been able to put to one side: 
 
…it’s got a lot to do wi’ the mental side of it like, y’know, because you’re 
really wanting this treatment a’ work an you’re conscious of it, you’re 
conscious of always being on this treatment, so likes, when I wasn’t I, I’d 
forget about it for months, I forgot all about I had hep C.  Y’know what I 
mean?  
(Steve, multi-tablet regimen) 
 
Emotional strain during the treatment process grew from the importance 
participants placed on being cured of HCV.  However, the impact on mental 
health from interferon-free treatment was considered and framed in respect to 
the imagined greater influence that interferon-based therapy would have, and 
as such its significance was diminished and symptoms became manageable.  
For example, the account above appeared towards the end of Steve’s narrative, 
almost as an afterthought or addendum.  Earlier in his interview Steve had 
described his treatment as “nowhere near as bad on your mental health as 
[interferon]” and how he “thought the medication was fantastic”.    
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Despite an impression of the side-effects of interferon-free therapy being 
comparatively innocuous, every participant drew attention to other difficulties 
which they had encountered during treatment.  The physical size of the tablets 
and the difficulty in swallowing them were emphasised, and for those on multi-
tablet regimens, a sense of being misled as to the simplicity of treatment 
became noticeable: 
 
The, the biggest thing that I think, was the fact when the new treatment 
came out it was, it sounded more like it was jus’ like more or less a 
single or two single type a’ tablets (…) even though the course was of 
three, four, five – ten different tablets that I was taking during the day 
anyway, so, that was the only thing that I was slightly sceptical in the 
way that that came across… 
(Gary, multi-tablet regimen) 
 
The accounts of participants on multi-tablet regimens underscored how the 
therapy was not taken in isolation, but incorporated into a life which was often 
already crowded with complex polypharmacy.  Opioid substitution therapy, 
anxiolytics, anti-psychotics and anti-retrovirals were just some of the 
medications participants reported as part of their daily routine.  Pill burden 
remained a significant feature of their course of treatment. 
 
Theme: an honour and a pleasure 
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The majority of participants related a largely positive and favourable account of 
their treatment, constructing their experience of interferon-free therapy as 
physically undemanding and relatively straightforward.  The short length of 
treatment and reduction in side-effects in relation to socially informed 
understandings of interferon-based therapy were framed as the most significant 
benefits of interferon-free regimens.  Participants who had previous first-hand 
encounters of interferon-based treatment were able to make contrasts with 
those eventful and side-effect laden experiences: 
 
…it was all easy, compared to the last time, ‘cause I…’cause I done the 
treatment, the interferon one, an’ compared to that, this was a breeze 
[laughs], this was like, jus’ like taking y’know, Lemsip or something… 
 
(Keith, single-tablet regimen) 
 
Whilst the participants’ narratives were largely positive in tone, a perception 
from some that they had been fortunate or lucky to access these treatments 
underpinned the discourse.  Those with histories of drug use described feeling 
guilty at what they perceived as good fortune of being in the right place at the 
right time, underlining an understanding that interferon-free therapy was not 
available to everyone, but a privilege and an honour.  For John, the guilt he 
experienced was rooted in his perception that some degree of atonement 
should be necessary to cure a disease which he felt he had brought upon 
himself.  The ease and simplicity of his treatment experience jarred with his 
 
 
18 
 
belief that a penance should be paid for the removal of HCV from his life, and 
that he had got away lightly compared to others he knew.  John felt he had 
escaped HCV with impunity, and this unsettled him: 
 
I’ll tell you why I felt guilty about it – I’ve got a really close friend who’s 
got like this medical situation, an’ he copes with it brilliantly, an’ he, erm, 
he hadn’t caused it himself or anything, he was jus’, y’know, erm, 
suffering from this condition an’ he has to struggle along an’ get on with 
it, y’know, an’ I’ve jus’ been more or less given a solution to my problem 
an’ have kind of got away with it scot-free. 
 
(John, multi-tablet regimen) 
 
In addition to feeling fortunate in comparison to other people, participants’ 
awareness of the cost of the drugs contributed to their sense of honour in 
receiving these therapies.  Whilst feelings of shock at the expense of the 
medications were voiced, these views contributed to a sense of privilege in 
gaining access to medications which were not universally available.  The price-
tags of these medications were not only discussed in relation to other 
treatments for HCV, but also in the context of distributive justice within other 
diseases:   
 
It makes me feel…bloody privileged, ‘cause, y’know what I mean, 
‘cause…no’ many people are getting that, I mean there’s people oot 
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there that’ve got cancers an’ stuff an’ they’re getting knocked back for 
treatments that cost that much. 
(Keith, single-tablet regimen) 
 
A few participants mentioned the media as the source of their information on 
medication costs.  However, a number of others implied that this knowledge 
was explicit in the discourse of the treating healthcare team, with participants 
trained in the price of their cure from an early stage: 
 
I knew that fae, the first week, how much these, all these cost an’ all 
that, I mean coming here you get taught, you get told what they’re trying 
a’ do here, an’ you find out how expensive they all are… 
 
(Stewart, single-tablet regimen) 
 
The narratives of some participants suggested the guilt and privilege felt at 
being able to access such expensive therapies had implications which extended 
beyond HCV therapy.  The experience of being prescribed these drugs 
strengthened, or built a resolve, that the investment made in them, both 
financially and personally, would reap long-term rewards: 
 
I feel sort a’, it makes me, it’ll make me think twice about going back 
taking drugs or alcohol or getting, going back on that kind a’ thing when 
you, you’ve been privileged enough for people a’ fight to get you better. 
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(Keith, single-tablet regimen) 
 
Theme: treatment needs 
The belief that HCV treatment should be an onerous undertaking, rather than a 
straightforward and undemanding process, constructed a compelling discourse 
relating how participants subsequently searched for signs and indicators that 
their treatment was working.  A need to substantiate the efficacy of the drugs 
permeated the participants’ narratives, shaping a perception that side-effects 
were almost desirable and advantageous: 
 
…when I came after four week I ask [the HCV nurse], she said do you 
feel anything?  Are you tired or this? An’ I say no, I say actually 
sometime I think I’m on a placebo, because there is no any effect at all. 
      
(Peter, single-tablet regimen) 
 
The hunt for side-effects increased the likelihood that any irregularities may be 
attributed to treatment, and relatively minor events such as single bouts of 
diarrhoea, or episodes of absent-mindedness were automatically ascribed to 
the medications.  The identification of possible side-effects was not the only 
method by which markers of efficacy were sought however.  The importance to 
participants of hearing how they were progressing through treatment from 
healthcare professionals also became a recurring refrain within the narratives.  
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The significance of receiving results from routine blood tests detailing the 
downward trajectory of the HCV viral load was repeatedly emphasised, situating 
them as beacons of reassurance, hope and motivation: 
 
…I started off really high, I was [x] million, which is very very high, an’ I 
went down to [states much lower figure] within three weeks – that’s 
impossible!  Err, so, it’s when you find out how quickly the treatment is 
working, err, in the first three week period an’ you’re thinking – that’s 
only three weeks, so it gives you that massive hope, y’know… 
 
(Steve, multi-tablet regimen) 
 
In addition, a couple of participants described a further instinctive approach to 
evaluating the effectiveness of treatment; they simply felt better whilst taking it.  
Primarily describing a feeling of reduced fatigue, this discourse was present in 
the narratives of those participants taking interferon- and ribavirin-free 
regimens: 
 
…maybe the hepatitis made me slow down but I didn’t realise, an’ I 
thought it was jus’ age!  An’ then I thought, I supposed to be feeling less 
energetic [on treatment], but, I want to do things all the time (….), it was 
fantastic, because I was feeling better after the four weeks, I say I feel 
more energy… 
(Peter, single-tablet regimen) 
 
 
22 
 
 
Support was framed in broad terms within the discourse, not solely focused on 
the practicalities of HCV treatment, but viewed more holistically, as caring for 
the complete individual.  Whilst support was acknowledged by all participants, a 
sharp contrast became evident in the perceived value and need for that support 
between participants who recounted extensive and graphic histories of drug 
use, and those who did not.  For those who did not, the support received, 
although highly regarded, was ultimately deemed unnecessary on retrospective 
reflection: 
 
No, no, not at all, no, no.  No.  Not with [this drug], nothing at all, I never 
felt I needed any support with [this drug], not at all, not at all.   
 
(Happy, single-tablet regimen) 
 
By contrast, the discourse from those with a history of drug use and drug 
dependence treatment emphasised the significance of support, highlighting its 
value to both practical and emotional aspects of therapy: 
 
…it is quite hard to jus’ keep it, doing it yourself (…) it’s really quite 
difficult, erm, you may think oh it’s easy jus’ take it err next, nine in the 
morning, nine at night, but likes, when you’re not working an’ you’re 
likes, err, like I said, really heavily medicated, it doesn’t work out like 
that… 
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(Steve, multi-tablet regimen) 
 
Interviewer: Was [the support received from the HCV treatment 
centre] important to you? 
 
Keith:  Aye, it was good to come here. 
 
Interviewer: Why? 
 
Keith:  The mental, the friendship, the feeling a’ care, people 
caring about you, d’you get what I mean? If you do that 
in the community you’re jus’ going in a’ see somebody, 
you’re getting your tablets an’ you’re fucking off for three 
months, it’s no’ gonna be the same.  You’re no’ gonna 
have that… 
 
(Keith, single-tablet regimen) 
 
For these individuals, support was portrayed as an expected, integral and 
essential component of the HCV treatment package, irrespective of the HCV 
drug combination or ease of therapy.  This is well illustrated by Danielle, who 
felt short-changed and cheated by her interferon-free course of therapy 
compared to other people she knew prescribed interferon-based regimens: 
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…oh, I don’t know how a’ explain this one really.  I think people are all 
getting treated differently, right, when you’re on triple therapy , right, 
you’re getting all the support, all the support, money-wise, mentally, the 
doctors, all the rest a’ it, this therapy you dunnae get nothing. 
 
(Danielle, single-tablet regimen) 
 
Of note, peer support was repeatedly mentioned as being of particular worth to 
this sub-group of participants.  They spoke of the immense value it had 
contributed to their experience, and positioned repaying that support, and using 
their own experience to benefit others, as a natural and obvious next step.  For 
Gary, this step had already been taken as he described placing himself at the 
centre of a local support network: 
 
…speaking out aloud at the group an’ being one of the fore [pauses] I 
was gonna say forefathers there!  Because we’ve jus’ kinda taken it 
from nowhere an’ we’ve put ourselves up for being this support, support 
group, now we’re looking at the angles where we can, can take things…  
 
(Gary, multi-tablet regimen) 
 
A nonconforming account 
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Gary’s experience of treatment grated with the predominant discourse emerging 
from the other participants.  Whilst the expectation of a demanding course of 
therapy was widely held, Gary was alone in having his worst expectations 
confirmed: 
 
…I started getting quite violently ill, sick, migraines, constant headaches 
were coming along, I spent about two weeks, literally, feeling like 
vomiting, couldn’t move off the sofa, lying in the same clothes, never 
had any energy, very lackadaisical, very very aggravated, I got myself 
so agitated, they ended up putting me on erm…[an antipsychotic], 
‘cause a’ my, I was so, getting so stressed… 
(Gary, multi-tablet regimen) 
 
Whilst Gary was not alone in experiencing side-effects, his account was 
unusual in the prominence he gave them.  He characterised his experience of 
treatment as one of illness and disorder, in contrast to other participants whose 
narratives mainly emphasised wellness and vitality punctuated by occasional 
complaints.  It is possible that these medications may have severe adverse side 
-effects for a minority of people taking them.  However, Gary’s narrative 
displayed a depth and intensity of expectation which was noticeable among the 
collected testimonies, and positioned his temporary illness as an absolute 
necessity in order for his therapy to be effective: 
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…I, I, I kinda got to that stage where I knew, for treatment to be 
successful, there’s gonna be, there’s gonna be elements a’ illness in 
there, it’s gonna do things to your body, so – aye, I kinda jus’ kept my 
mind in that… 
(Gary, multi-tablet regimen) 
 
…jus’ because I knew, listen, this is part of it, an’ I kinda structured my 
mind so I know I’ve gotta get ill to get better type a’ thing. 
 
(Gary, 38, multi-tablet regimen) 
 
Whilst initially appearing divergent from the prevailing discourse, Gary’s 
narrative strengthens and augments many key aspects of the themes found 
within the collected data, emphasising the importance of considering the 
themes collectively, rather than in isolation.  Although he did not describe the 
primarily positive experience of treatment constructed by the other participants, 
he acknowledged the luck he felt in receiving it, and assembled an account 
which reinforced the discourse concerning treatment needs and the hunt for 
efficacy.  Whilst it is possible that Gary experienced an atypical physiological 
reaction to the medication he was given, the side-effects he experienced may 
also have been borne of a belief that HCV therapy needed to be powerful, and 
the more toxicity he experienced, the greater the chance of the treatment 
working.  His testimony suggests that despite his difficulties, he believed the 
treatment he was taking was having a curative effect: 
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I never ever thought to myself I’m gonna stop this treatment, but there 
was, that niggling in the back of my head saying – can you carry on?  I 
thought, no, I’ve come this far, I’m, I’m not gonna back out an’ stop my 
treatment, no matter how hard-core it is… 
 
(Gary, 38, multi-tablet regimen) 
 
Discussion 
Quantitative reports of health-related quality of life during interferon-free HCV 
treatments have noted improvements in both mental and physical health 
domains compared to interferon-based regimens (Younossi et al, 2015a; 
Younossi et al, 2015b; Younossi et al, 2015c).  To date however, qualitative 
interpretations of the lived experience of these treatments have remained 
absent, preventing any contextual insights into the meaning of these numeric 
reports of ‘easier’ therapies.   
 
The experience of interferon-free HCV treatment is illustrated by the three 
themes previously described.  These themes do not exist in isolation, but 
interweave within and between each individual narrative, demonstrating how 
understandings which have been presented discretely, are necessarily 
intertwined.  For example, the self-monitoring and importance of support 
described within ‘treatment needs’ was not only the product of participants 
questioning an easier than expected treatment, but was also integral to the 
 
 
28 
 
construction of that positive experience.  That is not to say tensions do not exist.  
For example, the accounts of side-effects discussed in ‘expectations and 
realisations’ sit uneasily next to the discourse which described participants 
hunting for non-existent side-effects in ‘treatment needs’.  These two positions 
should be considered in counterpoise to one another, where equilibrium was 
maintained between the volume and intensity of side-effects experienced and 
the proactive search for further signs of efficacy.  This illustrates the way in 
which apparently contradictory aspects of these themes wax and wane in 
relation to each other, emphasising their fundamental interdependence. 
 
This study reveals the legacy of interferon-α currently casts a long shadow over 
the experience of interferon-free regimens, with the participant testimonies 
intricately tied to the historical touchstone of interferon-based treatment.  For 
example, discussion of side-effects continued to dominate the narratives.  
However, whilst the burden and severity of these ailments was the historical 
focus of concern (Hopwood & Treloar, 2005; Kinder, 2009; Sheppard & 
Hubbert, 2006), it was disbelief at the relative absence of side-effects which 
now took precedence within the participants’ accounts. 
 
The understanding of HCV therapy as a rigorous and demanding undertaking, 
informed the notion that effective treatment must be accompanied by toxicity 
and short-term suffering.  Insights gained from this study suggest participants 
actively sought out side-effects from interferon-free therapies as biomarkers for 
the effectiveness of the drugs, echoing reports from the interferon era which 
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found participants expecting to be unwell in order to get better (Taylor-Young & 
Hildebrandt, 2009).  Although not widely reported, this phenomenon has been 
noted in other disciplines, particularly in the fields of oncology and rheumatology 
(Goodacre & Goodacre, 2004; Gradishar, 2015; Lorish, Richards and Brown, 
1990), with periodic reports of patients requesting more aggressive and noxious 
therapies in the belief that these equate with improved efficacy (Gradishar, 
2015; Trusson & Pilnick, 2016).  This insight exposes a cultural lag between the 
rapid pharmacological developments which have been witnessed, and the 
social understanding of them, creating conflict between what patients ought to 
need, and what they actually require. 
 
Whilst the majority of participants recounted a relatively straightforward period 
of therapy (the exception being Gary), the discourse of luck and guilt was solely 
located in the narratives of those participants with histories of drug use.  This 
resonates with the acceptance of health inequalities, lack of entitlement, and the 
tolerance of rights violations which disenfranchised HCV communities have 
grown accustomed to over the years (Wolfe et al, 2015).  The discourse of luck 
and guilt positions those participants with histories of drug use as submissive 
recipients of healthcare, rather than active and emboldened consumers.  The 
absence of this narrative from the three participants who did not identify as drug 
users only serves to illustrate this point more effectively.  However, the 
‘privilege’ of treatment may also promote wider beneficial outcomes.  
Transformation narratives within the data suggest undertaking a course of 
interferon-free therapy may positively affect an individual’s self-worth, and aid 
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personal rehabilitation, consistent with previous studies conducted during the 
interferon era (Batchelder et al, 2015; Clark & Gifford, 2014; Rance & Treloar, 
2014). 
 
All participants in this study successfully completed their treatment regimen, 
and subsequently achieved an SVR.  Their treatment was delivered through a 
hospital-based clinic, however there is an emerging evidence base that moving 
therapy away from secondary care and into more diverse settings is a feasible 
objective (Alavi et al, 2013; Brew, Butt & Wright, 2013).  Interferon-based 
treatments have been successfully delivered in opioid substitution settings and 
prisons, achieving comparable adherence and response rates to those reported 
in more conventional locations (Grebely et al, 2016; Litwin et al, 2009; Rice et 
al, 2012), but these support-intensive models of treatment delivery may be 
reviewed in light of fewer perceived patient requirements with ‘easier’ drugs.  As 
interferon-free (and increasingly ribavirin-free) treatments proliferate, the clinical 
need for close haematological and side-effect monitoring of patients recedes 
(Lam et al, 2015), however the significance of knowing the treatment to be 
working, and the continued importance of support for individuals with significant 
histories of drug use and drug treatment are key findings within this analysis.  
Whilst the global HCV discourse tends to focus on improving SVR rates, 
reduced side-effect profiles and decreasing treatment times (Asselah et al, 
2016; Chung & Baumert, 2014; Pawlotsky et al, 2015), understanding what 
motivates and reassures individuals whilst taking the drugs is essential in 
ensuring improved adherence and integral to interferon-free treatments 
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reaching their full potential.  The cultural lag observed within this study suggests 
caution should be exercised in any reconsideration of how best to deliver 
interferon-free therapies to patients, as the experience of interferon-free 
treatment continues to demonstrate a significant and essential discourse of 
needs. 
 
How these needs are met is an important consideration.  The value placed on 
peer support was evident within the narratives, and emphasises that 
participants’ appreciated support which came from within their own communities 
and social networks.  Peer support has been recognised as an important factor 
in the facilitation of access to HCV services for populations that may experience 
significant barriers to accessing care (Crawford & Bath, 2013).  The ETHOS 
project in Australia has repeatedly demonstrated how peer support workers 
within opioid substitution clinics perform a valuable role in reducing barriers to 
HCV care and treatment, and how these workers are regarded as highly 
credible and trustworthy by those they support (Keats et al, 2015, Treloar et al, 
2015).  Peer support has been cited as one of ten priorities for expanding 
access to HCV treatment amongst drug users in low- and middle- income 
countries (Ford et al, 2015), and this study suggests its value also extends to 
other more traditional care settings in high-income nations. 
 
The differing account provided by Gary also highlights an important 
consideration; these themes and findings must be considered within the context 
of each individual person.  The nocebo phenomenon, in which placebos 
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produce adverse side-effects, can also offer insight into the reporting of 
nonspecific side-effects in patients taking active medications (Faasse & Petrie, 
2013).  Patient expectations and pre-treatment conditioning are often 
designated as key constituents of this phenomenon.  However, there are 
numerous personal, psychological, situational and contextual factors which 
have also been identified as potential components, such as learning from past 
experiences, and pre-existing anxiety and depression (Barsky et al, 2002).  
Whilst the thrust of this analysis stems from a realisation of largely unmet pre-
treatment expectations, there may be particular individuals whose specific set of 
circumstances and attributes allows those expectations to be realised.  Gary’s 
narrative accentuates the importance of a contextual understanding of 
interferon-free treatment. 
  
This study has a number of limitations.  The participants were all recruited from 
a hospital-based outpatient clinic, and may therefore be more engaged with 
healthcare and knowledgeable about HCV treatment.  The sample was also 
drawn from one treatment site within one geographical area, however the 
findings are transferable to other localities which have similar methods of 
treatment delivery and serve similar populations of individuals with HCV.  The 
sample size was also small, and the findings are therefore exploratory in nature.    
Finally, whilst the participants were prescribed different interferon-free 
therapies, the primary focus of analysis was not the variation between 
interferon-free regimens, but how HCV treatment is understood and 
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experienced when it no longer includes the one drug, interferon-α, which has 
defined and characterised it for over 20 years.   
 
Conclusion 
This is the first qualitative exploration of interferon-free HCV treatment reported 
globally.  It reveals that the perception of interferon-free treatment remains 
entwined with cultural understandings of interferon-based therapies.  Despite an 
acknowledgement that interferon-free treatment was less physically and 
emotionally demanding than expected, the importance of support and 
reassurance remained integral to the experience of therapy for those individuals 
with a significant history of drug use.  The way in which these medications are 
delivered in clinical practice now, and in the immediate future, should 
acknowledge and take these findings into account. 
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Table 1 
 
Table 1: Details of the four different HCV treatment regimens taken by participants. 
Treatment Regimen Single- or Multi-
Tablet Regimen 
Number of 
Participants 
Sofosbuvir/ledipasvir (Harvoni®): combination tablet taken once 
daily.  Licensed for use within Scotland for the treatment of HCV 
genotype 1 and 4, and for restricted use in genotype 3 (Scottish 
Medicines Consortium [SMC], 2015a). 
 
Single-Tablet 4 
Ombitasvir/paritaprevir/ritonavir (Viekirax®) + dasabuvir 
(Exviera®) + ribavirin: a combination tablet taken once daily, in 
conjunction with two twice daily medications.  Licensed within 
Scotland for the treatment of HCV genotype 1 {SMC, 2015b). 
 
Multi-Tablet 2 
Sofosbuvir (Sovaldi®) + daclatasvir (Daklinza®) + ribavirin: 
combination of two once daily tablets in conjunction with one 
twice daily medication.  Licensed in Scotland for use in the 
treatment of patients with significant fibrosis or compensated 
cirrhosis in genotypes 1,3 and 4 (SMC, 2014). 
 
Multi-Tablet 1 
Glecaprevir + pibrentasvir: fixed dose combination with 
pangenotypic action, currently in phase III clinical trials.  Not 
currently licensed for use in Scotland (UK Medicines Information, 
2016) 
 
Single-Tablet 1 
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Table 2 
 
Table 2: Demographic information for the eight participants.  All information was self-
reported by the participants during their initial interviews. 
Gender Male 6 
 Female 2 
Ethnicity UK 6 
 Other 2 
Age 0-39 1 
 40-49 2 
 50-59 5 
Opioid substitution therapy? Yes 3 
 No 5 
Mode of acquisition Injecting drug use 5 
 Other 3 
Date of diagnosis Up to 2011 4 
 2011 and after 4 
Degree of liver disease Pre-cirrhotic 6 
 Cirrhotic 2 
Previous interferon-based Yes 2 
HCV treatment? No 6 
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